Latest New Zealand News

Skin Elements Limited advances its natural biotechnology products with ECO-Nurture trials concluding and SuprCuvr disinfectant gaining traction, supported by a successful $656k capital raise.

Echelon Resources delivered a robust March 2025 quarter with production volumes up 5% and development wells at Mereenie surpassing expectations. The company also moved to acquire full operatorship of EP145 in the Amadeus Basin, signaling strategic growth despite exploration setbacks.

Dimerix Limited advances its Phase 3 kidney disease trial with FDA acceptance of proteinuria as a primary endpoint and clinches a lucrative licensing agreement in Japan worth up to AU$107 million plus royalties.

betr Entertainment has successfully raised $130 million through a fully underwritten equity offer priced at a 13.7% premium, underpinning its strategic acquisition of PointsBet and positioning for growth in the Australian wagering market.

MedAdvisor Solutions reported a challenging third quarter with steep revenue declines, driven by delayed program launches and US sales underperformance, but is executing a strategic overhaul and cost-cutting measures to position for a rebound and 15% revenue growth in FY26.

MedAdvisor Limited reports a steep decline in 3Q FY25 revenue, driven by US market challenges, while accelerating cost-cutting and reaffirming full-year guidance.

Tissue Repair Limited reports progress in its Phase 3 clinical trials for TR987® despite enrollment delays caused by US regulatory disruptions, while TR Pro+® sales hit record highs and manufacturing scale-up advances.

Horizon Oil reported steady Q3 FY25 production and cash flow, paid its fifth consecutive interim dividend, and announced a strategic acquisition in Thailand that promises to boost production and diversify its asset base.

Zoom2u Technologies reports steady group revenue with Locate2u growing 10%, supported by AI initiatives that cut staff costs and a $0.5 million capital raise.

Cluey Ltd reported a 24% surge in new student enrolments in Q3 FY25 alongside a 46% reduction in cash burn, signaling improved operational efficiency and a clearer path to profitability.

Orthocell has secured Health Canada approval for its nerve repair product Remplir™, adding the US$75 million Canadian market and expanding its total addressable market to US$1.8 billion. The company plans to appoint local distributors and expects first sales in H2 2025.

Galan Lithium has locked in a binding funding and offtake agreement with Authium Limited for its Hombre Muerto West project, significantly reducing capital and operating costs. The company raised approximately A$13 million via placement and plans further shareholder funding, aiming for lithium chloride production in H1 2026.